Company profile: Cell IDx
1.1 - Company Overview
Company description
- Provider of multiplexed cellular immunodiagnostics solutions, developing highly sensitive and specific reagents for research and clinical immunohistochemistry, and offering UltraPlex technology for multiplex chromogenic and fluorescent tissue staining suitable for high-throughput biomarker tissue profiling.
Products and services
- UltraPlex Technology: Engineers multiplex chromogenic and fluorescent tissue staining, suitable for high-throughput multiplex biomarker tissue profiling in research and clinical immunohistochemistry workflows
- Highly Sensitive and Specific Immunohistochemistry Reagents: Creates reagents for research and clinical immunohistochemistry delivering high-specificity, high-sensitivity staining performance on tissue sections in research and clinical settings
- High-Throughput Multiplex Biomarker Tissue Profiling: Enables tissue profiling with multiplex chromogenic and fluorescent staining to assess biomarkers concurrently in high-throughput studies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cell IDx
Noveome Biotherapeutics
HQ: United States
Website
- Description: Provider of regenerative repair therapies for inflamed or damaged tissues via ST266, a multi-targeted secretome of biologically active proteins for neuroprotection, inflammation modulation, cell recovery, and healing in ophthalmology, neurology, and dermatology; explored in PEDs, optic neuritis, glaucoma (Phase I), NEC, and COVID-19/sepsis cytokine storm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Noveome Biotherapeutics company profile →
TxCell
HQ: France
Website
- Description: Provider of cell-based immuno-therapies for severe chronic inflammatory diseases with high medical need, using unique proprietary technology; a spin-off of Inserm based in Sophia Antipolis near Nice, France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TxCell company profile →
Epiva
HQ: United States
Website
- Description: Provider of immuno-microbiome therapeutics, developing immunobiotic therapeutics through a platform from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epiva company profile →
EpiBiologics
HQ: United States
Website
- Description: Provider of antibody-based targeted therapies and platforms for tissue-specific degradation of disease-driving membrane and extracellular proteins, including the EpiTAC platform (bispecific antibody system), AbTACs, KineTACs, TrainTAC degrader, and the EpiAtlas platform with a library of over 270 degrader arms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EpiBiologics company profile →
Amira Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule pharmaceutical research focused on the discovery and early development of new drugs to treat inflammatory disease, leveraging unparalleled insights into bioactive lipid pathways and complex signaling processes controlling conditions including asthma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amira Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cell IDx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cell IDx
2.2 - Growth funds investing in similar companies to Cell IDx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cell IDx
4.2 - Public trading comparable groups for Cell IDx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →